A PKA inhibitor
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

PKI (14-22) amide (myristoylated) (trifluoroacetate salt)

Item No. 34431

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-(1-oxotetradecyl)glycyl-L-arginyl-L-threonylglycyl-L-arginyl-L-arginyl-L-asparaginyl-L-alanyl-L-isoleucinamide, trifluoroacetate salt
Synonyms
  • Myr-Gly-Arg-Thr-Gly-Arg-Arg-Asn-Ala-Ile-NH2
  • Myr-GRTGRRNAI-NH2
  • Myristoylated PKI-(14-22)-amide
  • PKI-(Myr-14-22)-amide
Molecular Formula
C53H100N20O12 • XCF3COOH
Formula Weight
1209.5
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: 1 mg/mlDMSO:PBS (pH 7.2) (1:3): 0.25 mg/ml
SMILES
O=C(CCCCCCCCCCCCC)NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@H](O)C)C(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(N)=O)C(N[C@@H](C)C(N[C@H](C(N)=O)[C@@H](C)CC)=O)=O)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O
InChi Code
InChI=1S/C53H100N20O12.C2HF3O2/c1-6-8-9-10-11-12-13-14-15-16-17-24-39(76)65-29-40(77)69-35(22-19-26-63-52(58)59)48(83)73-43(33(5)74)50(85)66-30-41(78)68-34(21-18-25-62-51(56)57)46(81)70-36(23-20-27-64-53(60)61)47(82)71-37(28-38(54)75)49(84)67-32(4)45(80)72-42(44(55)79)31(3)7-2;3-2(4,5)1(6)7/h31-37,42-43,74H,6-30H2,1-5H3,(H2,54,75)(H2,55,79)(H,65,76)(H,66,85)(H,67,84)(H,68,78)(H,69,77)(H,70,81)(H,71,82)(H,72,80)(H,73,83)(H4,56,57,62)(H4,58,59,63)(H4,60,61,64);(H,6,7)/t31-,32-,33+,34-,35-,36-,37-,42-,43-;/m0./s1
InChi Key
DBHNUJXUTKVLID-UXBYPZMDSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $121

    Add

    1 mg

    $215

    Add

    5 mg

    $655

    Add
    Kinase Resource Center
    Discover Products & Resources for Kinase Research
    • Kinase inhibitors, screening libraries, assay kits, & more
    • Tools to study kinase signaling pathways:
      • Growth factor signaling
      • PI3K/Akt/mTOR
      • MAPKs (ERK, p38, & JNK)
      • JAK/STAT signaling
    • Articles, resources, & advice
    EXPLORE NOW
    Product Description

    PKI (14-22) amide (myristoylated) is a cell-permeable peptide inhibitor of protein kinase A (PKA).1,2,3 It inhibits PKA activity in mouse brain or spinal cord lysates when used at a concentration of 75 µM.1 PKI (14-22) amide (myristoylated) reduces IgG-dependent phagocytosis of heat-killed S. cerevisiae by isolated human neutrophils in a concentration-dependent manner.2 It inhibits the replication of several strains of Zika virus, including IbH 30656, MR766, H/FP/2013, and PRVABC59, in human umbilical vein endothelial cells (HUVECs; IC50s = 17.75, 22.29, 34.09, and 19.19 µM, respectively).3 PKI (14-22) amide (myristoylated) (2.5 nmol, i.c.v.) increases latency to tail withdrawal in the tail-flick test in morphine-tolerant mice.1

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Dalton, G.D., Smith, F.L., Smith, P.A., et al. Alterations in brain Protein Kinase A activity and reversal of morphine tolerance by two fragments of native Protein Kinase A inhibitor peptide (PKI). Neuropharmacology 48(5), 648-657 (2005).

    2. Ydrenius, L., Majeed, M., Rasmusson, B.J., et al. Activation of cAMP-dependent protein kinase is necessary for actin rearrangements in human neutrophils during phagocytosis. J. Leukoc. Biol. 67(4), 520-528 (2000).

    3. Cheng, F., da Silva, S.R., Huang, I.-C., et al. Suppression of Zika virus infection and replication in endothelial cells and astrocytes by PKA inhibitor PKI 14-22. J. Virol. 92(4), e02019-02017 (2018).